Advanced search
Publication Cover
Leukemia & Lymphoma Volume 54, 2013 - Issue 11
Submit an article Journal homepage
937
Views
25
CrossRef citations to date
0
Altmetric
Research Article

Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy

Esther N. Oliva“Bianchi-Melacrino-Morelli” Hospital, Reggio Calabria, ItalyCorrespondence[email protected] [email protected]
,
Roberto Latagliata“La Sapienza” University, Rome, Italy
,
Carmelo Laganà“Bianchi-Melacrino-Morelli” Hospital, Reggio Calabria, Italy
,
Massimo Breccia“La Sapienza” University, Rome, Italy
,
Sara GalimbertiSt. Chiara Hospital, University of Pisa, Pisa, Italy
,
Fortunato MorabitoAnnunziata Hospital, Cosenza, Italy
,
Antonella PoloniMarche Polytechnic University, Ancona, Italy
,
Enrico BalleariSan Martino Hospital, Genoa, Italy
,
Agostino CortelezziIRCCS Ca’ Granda Fundation, Polyclinic, University of Milan, Milan, Italy
,
Giuseppe Palumbo“V. Emanuele” Polyclinic, Catania, Italy
,
Grazia Sanpaolo“Casa Sollievo della Sofferenza” Hospital, San Giovanni Rotondo, Italy
,
Antonio VolpeSan Giuseppe Moscati Hospital, Avellino, Italy
,
Giorgina SpecchiaUniversity of Bari, Bari, Italy
,
Carlo FinelliUniversity of Bologna, Bologna, Italy
,
Maria Grazia D’Errigo“Bianchi-Melacrino-Morelli” Hospital, Reggio Calabria, Italy
,
Filippo Rodà“Bianchi-Melacrino-Morelli” Hospital, Reggio Calabria, Italy
,
Caterina Alati“Bianchi-Melacrino-Morelli” Hospital, Reggio Calabria, Italy
,
Giuliana AlimenaSt. Chiara Hospital, University of Pisa, Pisa, Italy
,
Francesco Nobile“Bianchi-Melacrino-Morelli” Hospital, Reggio Calabria, Italy
&
Maria A. Aloe SpiritiSant’Andrea Hospital, Rome, Italy
 show all
Pages 2458-2465 | Received 06 Jan 2013, Accepted 18 Feb 2013, Published online: 27 Mar 2013

Citations (25)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Jonathan Feld, Abigail Belasen & Shyamala C Navada. (2020) Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years. Expert Review of Anticancer Therapy 20:6, pages 465-482.
Read now
Rory M. Shallis, Nora Chokr, Maximilian Stahl, Alexander B. Pine & Amer M. Zeidan. (2018) Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place. Expert Review of Hematology 11:9, pages 715-726.
Read now
Gabriele Gugliotta, Fausto Castagnetti, Miriam Fogli, Michele Cavo, Michele Baccarani & Gianantonio Rosti. (2013) Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors. Expert Review of Hematology 6:5, pages 563-574.
Read now

Articles from other publishers (22)

Huan Li, Fang Hu, Robert Peter Gale, Mikkael A. Sekeres & Yang Liang. (2022) Myelodysplastic syndromes. Nature Reviews Disease Primers 8:1.
Crossref
Valeria Santini, Aristoteles Giagounidis, Christopher G. Pelligra, Conrado Franco-Villalobos, Derek Tang, Jessica Morison, CL Beach, Angela Hu, Uwe Platzbecker & Pierre Fenaux. (2022) Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes. Clinical Lymphoma Myeloma and Leukemia 22:9, pages e874-e883.
Crossref
Esther Natalie Oliva, Uwe Platzbecker, Guillermo Garcia-Manero, Ghulam J. Mufti, Valeria Santini, Mikkael A. Sekeres, Rami S. Komrokji, Jeevan K. Shetty, Derek Tang, Shien Guo, Weiqin Liao, George Zhang, Xianwei Ha, Rodrigo Ito, Jennifer Lord-Bessen, Jay T. Backstrom & Pierre Fenaux. (2021) Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial. Journal of Clinical Medicine 11:1, pages 27.
Crossref
Esther N. Oliva, Uwe Platzbecker, Pierre Fenaux, Guillermo Garcia-Manero, Thomas W. LeBlanc, Bhumika J. Patel, Anne Sophie Kubasch & Mikkael A. Sekeres. (2021) Targeting health-related quality of life in patients with myelodysplastic syndromes – Current knowledge and lessons to be learned. Blood Reviews 50, pages 100851.
Crossref
Simona Pagliuca, Carmelo Gurnari & Valeria Visconte. (2021) Molecular Targeted Therapy in Myelodysplastic Syndromes: New Options for Tailored Treatments. Cancers 13:4, pages 784.
Crossref
Xiaofang Chen, Ningyu Li, Jianyu Weng & Xin Du. (2021) Senescent Mesenchymal Stem Cells in Myelodysplastic Syndrome: Functional Alterations, Molecular Mechanisms, and Therapeutic Strategies. Frontiers in Cell and Developmental Biology 8.
Crossref
Esther Natalie Oliva & Giovanni Luigi Tripepi. (2020) Letter to the Editor on the original article “A systematic review of patient reported outcomes in phase II or III clinical trials of myelodysplastic syndromes and acute myeloid leukemia” by Bryant Al, et al. 2018. Leukemia Research 93, pages 106355.
Crossref
Sung-Yong Kim. (2020) Lenalidomide for the Treatment of Myelodysplastic Syndrome. The Korean Journal of Medicine 95:2, pages 74-77.
Crossref
Ulrich Germing, Ester N. Oliva, Devendra Hiwase & Antonio Almeida. (2019) Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies. HemaSphere 3:6, pages e314.
Crossref
Pushpendra Goswami, Yasmin Khatib & Sam Salek. (2019) Haematological malignancy: Are we measuring what is important to patients? A systematic review of quality‐of‐life instruments. European Journal of Haematology 102:4, pages 279-311.
Crossref
Claudio Fozza. (2019) Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant. Critical Reviews in Oncology/Hematology 133, pages 112-119.
Crossref
Irene M. Ghobrial, Alexandre Detappe, Kenneth C. Anderson & David P. Steensma. (2018) The bone-marrow niche in MDS and MGUS: implications for AML and MM. Nature Reviews Clinical Oncology 15:4, pages 219-233.
Crossref
Valeria Santini, Antonio Almeida, Aristoteles Giagounidis, Uwe Platzbecker, Rena Buckstein, C.L. Beach, Shien Guo, Arman Altincatal, Chengqing Wu & Pierre Fenaux. (2018) The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study. Clinical Lymphoma Myeloma and Leukemia 18:2, pages 136-144.e7.
Crossref
F. Ramos, C. Pedro, M. Tormo, R. de Paz, P. Font, E. Luño, M. Caballero, F. Solano, M. Almagro, B. Xicoy & M. Jiménez. (2017) Impact of anaemia on health-related quality of life and cardiac remodelling in patients with lower risk myelodysplastic syndromes. Results of GlobQoL study. European Journal of Cancer Care 26:6, pages e12426.
Crossref
Maximilian Stahl & Amer M. Zeidan. (2017) Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications. Cancer 123:10, pages 1703-1713.
Crossref
Xin-yue Lian, Zhi-hui Zhang, Zhao-qun Deng, Pin-fang He, Dong-ming Yao, Zi-jun Xu, Xiang-mei Wen, Lei Yang, Jiang Lin & Jun Qian. (2016) Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis. PLOS ONE 11:11, pages e0165948.
Crossref
Nitin Sood, Bhuvan Chugh, Esha Singhal, Ritesh Sachdev, Shalini Goel & Gajendra Smeeta. (2016) Myelodysplastic syndromes: Where do we stand?. Asian Journal of Oncology 02, pages 014-022.
Crossref
R.S. Komrokji & A.F. List. (2016) Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes. Annals of Oncology 27:1, pages 62-68.
Crossref
Esther N. Oliva, Michael Lauseker, Maria Antonietta Aloe Spiriti, Antonella Poloni, Agostino Cortelezzi, Giuseppe A. Palumbo, Enrico Balleari, Grazia Sanpaolo, Antonio Volpe, Alessandra Ricco, Francesca Ronco, Caterina Alati, Maria Grazia D'Errigo, Irene Santacaterina, Andrea Kündgen, Ulrich Germing & Roberto Latagliata. (2015) Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence. Cancer Medicine 4:12, pages 1789-1797.
Crossref
Valeria Santini. (2015) Anemia as the Main Manifestation of Myelodysplastic Syndromes. Seminars in Hematology 52:4, pages 348-356.
Crossref
Federico Vozella, Roberto Latagliata, Ida Carmosino, Paola Volpicelli, Chiara Montagna, Angela Romano, Amanda Roberto, Paola Finsinger, Marco Mancini, Massimo Breccia, Esther Oliva & Giuliana Alimena. (2015) Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?. Hematological Oncology 33:1, pages 48-51.
Crossref
Yahiya Y. Syed & Lesley J. Scott. (2013) Lenalidomide: A Review of its Use in Patients with Transfusion-Dependent Anaemia due to Low- or Intermediate-1-Risk Myelodysplastic Syndrome Associated with 5q Chromosome Deletion. Drugs 73:11, pages 1183-1196.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.